Linderane – 5 mg

Brand:
Cayman
CAS:
13476-25-0
Storage:
-20
UN-No:
Non-Hazardous - /

Linderane is a sesquiterpene that has been found in L. aggregata.{45215,45216} It inhibits the cytochrome P450 (CYP) isoform CYP2C9 (Ki = 1.26 μM) in an irreversible and NADPH-dependent manner.{45215} Linderane decreases phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase (G6pc) gene expression, cAMP concentration, and CREB phosphorylation, increases phosphodiesterase 3 (PDE3) activity, and inhibits gluconeogenesis in rat primary hepatocytes.{45216} In vivo, linderane (50 mg/kg twice per day) decreases serum and hepatic triglyceride levels, as well as random-fed and fasting blood glucose levels in ob/ob mice.  

 

Available on backorder

SKU: 27479 - 5 mg Category:

Description

A sesquiterpene; inhibits CYP2C9 (Ki = 1.26 μM); reduces Pck1 and G6pc gene expression, cAMP concentration, and CREB phosphorylation, increases PDE3 activity, and inhibits gluconeogenesis in rat primary hepatocytes; decreases serum and hepatic triglyceride levels, as well as random-fed and fasting blood glucose levels in ob/ob mice


Formal name: (1aS,4E,10S,10aS)-3,6,10,10a-tetrahydro-5,9-dimethyl-2H-10,1a-(epoxymethano)oxireno[4,5]cyclodeca[1,2-b]furan-12-one

Synonyms: 

Molecular weight: 260.3

CAS: 13476-25-0

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Natural Products|Terpenes||Product Type|Biochemicals|Small Molecule Inhibitors|Cytochrome P450||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Toxicology|Drug Metabolism|Cytochrome P450